Form 8-K - Current report:
SEC Accession No. 0001437749-25-016598
Filing Date
2025-05-14
Accepted
2025-05-14 07:30:28
Documents
16
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250513_8k.htm   iXBRL 8-K 22802
2 EXHIBIT 99.1 ex_817237.htm EX-99.1 99767
7 image1.jpg GRAPHIC 9698
  Complete submission text file 0001437749-25-016598.txt   299222

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250514.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250514_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250514_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250514_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250513_8k_htm.xml XML 2846
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 25942649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)